FP prostanoid receptor Inhibitors
4 drugsAbout FP prostanoid receptor
The FP prostanoid receptor (PTGFR), also known as the prostaglandin F2α receptor, is a GPCR that binds prostaglandin F2α, a lipid mediator involved in various physiological processes.
Genetic studies provide moderate support for PTGFR as a therapeutic target, with a max genetic score of 0.50 linked to disorder of ear. Colocalization analysis reveals 19 strong eQTL/pQTL signals (max H4: 1.00), suggesting potential regulatory mechanisms.
Four FDA-approved small molecule drugs, including TAFLUPROST, IDOSE TR, ZIOPTAN, and TRAVATAN Z, target PTGFR, primarily in ophthalmology. These drugs are used to manage intraocular pressure, highlighting the receptor's druggability.
FP prostanoid receptor Genetic Evidence Moderate
Genetic evidence offers moderate support for PTGFR, with a max score of 0.50.
Further investigation of high colocalization signals could reveal novel therapeutic opportunities.
Evidence Across Diseases
13 totalGWAS and other genetic studies link PTGFR to 13 diseases.
🔗 Colocalization Evidence 19 strong
max H4: 1.00eQTL/pQTL signals for PTGFR colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top FP prostanoid receptor Drugs
Four companies, including INGENUS PHARMS LLC and Novartis, have approved drugs targeting PTGFR.
The presence of multiple established players suggests a moderately competitive market with potential entry barriers.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| ZIOPTAN | THEA PHARMA | 2012 | - |
FP prostanoid receptor Drug Modality Landscape
Modalities
Routes of Administration
FP prostanoid receptor is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides could diversify the therapeutic landscape.
FP prostanoid receptor Clinical Trials 90 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FP prostanoid receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 15 | 13 | 1 | 1 | 93% |
| Phase 3 | 25 | 19 | 4 | 2 | 83% |
| Phase 4 | 46 | 39 | 5 | 2 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FP prostanoid receptor Drug Approval Timeline (2006 - 2023)
The first drug was approved in 2006, with the most recent approval in 2023.
The 18-year span indicates sustained interest, but recent approval suggests potential for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 31 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FP prostanoid receptor. A trial counts if an approved drug acting on FP prostanoid receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.